ClinicalTrials.gg
CompletedNCT05531097Updated Jan 3, 2024

Ascending Single-Dose and Multiple-Dose Study to Evaluate HSK31679 in Healthy Subjects and Subjects With Elevated LDL-C

A Phase 1 interventional study of HSK31679 and Placebo in Healthy and Elevated LDL-C, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-03.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Feb 2022, registered Aug 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a Phase I, single-dose and multiple dose escalation clinical trial for HSK31679 conducted in chinese healthy volunteers and LDL-C elevated subjects. The safety, tolerability, food-impact,pharmacokinetics and pharmacodynamics of HSK31679 tablet in healthy volunteers and LDL-C elevated volunteers will be evaluated using a randomized, double-blind, placebo-controlled trial design

02

Conditions studied

  • Healthy
  • Elevated LDL-C

Keywords

  • HSK31679
  • Healthy
  • Elevated LDL-C
  • Phase I
03

In context

Lead sponsor

Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject must be willing and able to provide written .
  2. At the time of screening, eligibility criteria for SAD part are 18 to 55 years of age , and eligibility criteria for MAD part are 18 to 60 years of age , both male and female.
  3. ≥ 18.0 and ≤ 30.0 kg/m2, with a body weight ≥ 45 kg at Screening.
  4. LDL cholesterol ≥ 70mg/dL for SAD part and LDL cholesterol ≥ 100mg/dL for MAD part.
  5. Triglyceride \<400 mg/dL.
  6. Medically healthy without abnormalities at Screening and predose on Day 1, including:

    1. Physical examination without any clinically relevant findings.
    2. Heart rate in the range of 50 to 100 bpm after 5 minutes rest in supine position or seated.
    3. Body temperature, between 35.0°C and 37.7°C.
    4. Three conventional 12- recordings (the average of the three measurements will be used to determine eligibility) were consistent with normal cardiac conduction and function.
  7. Fertile male and female subjects agree to use appropriate physical during the study and for 6 months after the last dose.
  8. Willing and able to comply with all study evaluations and adhere to protocol schedules and constraints.
  9. Additional inclusion criteria for SAD and MAD subjects who are not treated with statins: Systolic blood pressure in the range of 90 to 139 mmHg and diastolic blood pressure in the range of 60 to 89 mmHg after 5 minutes in supine position or seated.
  10. Additional inclusion criteria for MAD subjects who are treated with statins:

    1. Systolic blood pressure in the range of 90 to 160 mmHg and diastolic blood pressure in the range of 60 to 100 mmHg after 5 minutes in supine position or seated.
    2. A stable dose of a statin (simvastatin atorvastatin or rosuvastatin) is administered daily for 28 days before randomization.

Exclusion criteria

Exclusion Criteria:

  1. history or presence of major diseases of the cardiovascular, respiratory, digestive, urological, hematologic, endocrine, immunologic, skin or nervous system, as well as any acute illness or surgical procedure within the past 3 months as determined by the investigator to be . Any clinically significant uncontrolled endocrine or immune disease known to affect lipid or lipoprotein levels.
  2. Current infection requiring treatment with antibiotics, antifungal, antiparasitic, or antiviral agents.
  3. Any history of within the last 10 years.
  4. Previous thyroid related disease and/or abnormal thyroid function tests during screening are clinically significant.
  5. Laboratory tests during the screening period were abnormal and clinically significant as judged by the investigator . [The abnormal elevation of lipid related indexes in MAD patients who met the inclusion criteria and the values of (ALT) and aspartate aminotransferase (AST) 2.0 due to long-term stable use of statins were not considered as the basis for exclusion].
  6. surface antigen (HBsAg), antibody (HCVAb), syphilis antibody and (HIV) antibody test are positive at screening.
  7. Have gastrointestinal, liver, kidney, or other diseases known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
  8. History of drug abuse in the 12 months prior to the first administration of the study drug or alcohol abuse in the 3 months prior.
  9. A clinically significant allergic reaction that the investigator believes interferes with the subject's ability to participate in the trial; Known allergies to any of the study drug ingredients.
  10. Any was administered within 30 days prior to the first administration of the study drug.
  11. Pregnant or lactating women.
  12. Donate blood or plasma within 3 months prior to the first administration of the study drug, or lose more than 500mL of whole blood, or receive blood transfusion within 1 year prior to the first administration of the study drug.
  13. History of Participating in another clinical trial within 90 days before the first administration of the study drug.
  14. Any other factors considered by the investigator to be inappropriate for participation in the trial.
  15. Additional exclusion criteria for SAD subjects: Use of any prescription and over-the-counter drugs during the 14 days prior to the first administration of the study drug or during the 5 half-lives of the drug, whichever is longer, unless deemed by both the investigator and the sponsor to be of no clinical relevance and not to affect lipid levels.
  16. Additional exclusion criteria for MAD subjects:

    1. Use of any prescription and over-the-counter drugs during the 14 days prior to the first administration of the study drug or during the 5 half-lives of the drug, whichever is longer, unless deemed by both the investigator and the sponsor to be of no clinical relevance and not to affect lipid levels.Blood pressure medications (up to 2 blood pressure medications per subject) are permitted, and subjects who are treated with statins are allowed to take a stable dose of simvastatin, atorvastatin or rosuvastatin according to the protocol.
    2. Patients with homozygous familial hypercholesterolemia (HoFH).
    3. Secondary dyslipidemia.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    HSK31679

    Drug: HSK31679

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Single or multiple oral doses of HSK31679

  • DrugPlacebo

    Matching placebo

06

What researchers measure

Primary outcomes

  1. The number and severity of treatment emergent adverse events (TEAEs) .

    To assess the safety and tolerability of single or multiple oral dose of HSK31679 in healthy or LDL-C elevated adult volunteers

    Time frame: 5 days after single dose and 18 days after the first dose of multiple doses

  2. Changes from baseline in clinical laboratory parameters(Blood routine, blood biochemistry, Urine routine, Coagulation function, thyroid function and antibodies).

    To assess the safety and tolerability of single or multiple oral dose of HSK31679 in healthy or LDL-C elevated adult volunteers

    Time frame: 5 days after single dose and 18 days after the first dose of multiple doses

  3. Changes from baseline in physical examination results(General condition skin mucous membrane superficial lymph nodes head neck chest abdomen spine limbs and others).

    To assess the safety and tolerability of single or multiple oral dose of HSK31679 in healthy or LDL-C elevated adult volunteers

    Time frame: 5 days after single dose and 18 days after the first dose of multiple doses

  4. Changes from baseline in vital signs(Systolic and diastolic blood pressure, pulse, respiratory rate, body temperature).

    To assess the safety and tolerability of single or multiple oral dose of HSK31679 in healthy or LDL-C elevated adult volunteers

    Time frame: 5 days after single dose and 18 days after the first dose of multiple doses

  5. Changes from baseline in 12-ECG(QT interval, QTcF interval, PR interval, QRS interval and RR interval).

    To assess the safety and tolerability of single or multiple oral dose of HSK31679 in healthy or LDL-C elevated adult volunteers

    Time frame: 5 days after single dose and 18 days after the first dose of multiple doses

Secondary outcomes

  1. Plasma concentration of HSK31679

    Assessed with or without food in single dose Assessed with or without stains in multiple doses

    Time frame: 0 to 24 hours on Day 1 and Day 14

  2. Lipid level changes following administration of HSK31679

    Assessed with or without stains in multiple doses

    Time frame: Day 1 to Day 14

07

Study locations

2 sites
  • Peking University First Hospital
    Beijing, Beijing, China
  • Xiangya Hospital of Central South University
    Changsha, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Sep 2022, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2022
First posted
Sep 7, 2022
StartActual
Feb 22, 2022
Primary completionActual
Sep 21, 2022
CompletionActual
Dec 8, 2022
Last update
Jan 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05531097
Responsible party
Sponsor
First posted
Sep 7, 2022
Start date
Feb 22, 2022
Primary completion
Sep 21, 2022
Completion
Dec 8, 2022
Last update
Jan 3, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK31679

Start the discussion